University Family Physicians, Inc. | |
1701 N Senate Blvd Indianapolis IN 46202-1239 | |
(317) 962-2000 | |
Not Available |
Full Name | University Family Physicians, Inc. |
---|---|
Speciality | Family Medicine |
Location | 1701 N Senate Blvd, Indianapolis, Indiana |
Authorized Official Name and Position | Judith L Coleman (CFO) |
Authorized Official Contact | 3179483525 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
University Family Physicians, Inc. 250 N Shadeland Ave Indianapolis IN 46219-4959 Ph: (888) 484-3258 | University Family Physicians, Inc. 1701 N Senate Blvd Indianapolis IN 46202-1239 Ph: (317) 962-2000 |
NPI Number | 1043275787 |
---|---|
Provider Enumeration Date | 04/18/2006 |
Last Update Date | 11/03/2023 |
Medicare PECOS PAC ID | 7911992797 |
---|---|
Medicare Enrollment ID | O20040420000393 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1043275787 | NPI | - | NPPES |
100059030 | Medicaid | IN |
Provider Name | Scott E Renshaw |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1629034392 PECOS PAC ID: 7911810643 Enrollment ID: I20031110000270 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Harold J Hileman |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1730129032 PECOS PAC ID: 2062319478 Enrollment ID: I20031215000588 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Wayne M Ellis |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1508848102 PECOS PAC ID: 8527953413 Enrollment ID: I20040219000199 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael Summers |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1891719324 PECOS PAC ID: 3476442302 Enrollment ID: I20040310001445 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bryan E Hainline |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1154431567 PECOS PAC ID: 4789574609 Enrollment ID: I20040316000872 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mitchell Alan Harris |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1285741942 PECOS PAC ID: 6305738949 Enrollment ID: I20040327000211 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Coby T Richeson |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1700835204 PECOS PAC ID: 4981698727 Enrollment ID: I20040413001591 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bradley M Sutter |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1568467645 PECOS PAC ID: 8527056134 Enrollment ID: I20040503001547 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jerome B Sneed |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1053492868 PECOS PAC ID: 5193716686 Enrollment ID: I20040522000218 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Melanie A Pickett |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1346219003 PECOS PAC ID: 0446240303 Enrollment ID: I20040604000528 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Wynter K Vik |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1235188137 PECOS PAC ID: 4082696695 Enrollment ID: I20040607000075 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Blaine Y Takesue |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1225046089 PECOS PAC ID: 2264414762 Enrollment ID: I20040607000767 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Holly M Hendrickson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1699733592 PECOS PAC ID: 8628052107 Enrollment ID: I20040614000799 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Derek T Sprunger |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1184625311 PECOS PAC ID: 8426032434 Enrollment ID: I20040616001396 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carol Lynn Dellinger |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1689663031 PECOS PAC ID: 8527043983 Enrollment ID: I20040621000572 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gavin J Roberts |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1477555035 PECOS PAC ID: 3779563358 Enrollment ID: I20040728000047 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | William G Zeh |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1932137668 PECOS PAC ID: 6204749534 Enrollment ID: I20040820000699 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | John Latona |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1497700983 PECOS PAC ID: 3375516370 Enrollment ID: I20040820000719 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Beth A Barron |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1679680151 PECOS PAC ID: 7214902352 Enrollment ID: I20040831001568 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Xiaoyan Wang |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1700844818 PECOS PAC ID: 1557337367 Enrollment ID: I20040902001208 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Dana L Donaldson |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1649271867 PECOS PAC ID: 8820057698 Enrollment ID: I20041007000196 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Susan M Hunt |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1740204668 PECOS PAC ID: 4183683691 Enrollment ID: I20041008000662 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David D Weaver |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1508822545 PECOS PAC ID: 6305808403 Enrollment ID: I20041101000751 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Eric A Albright |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1437135506 PECOS PAC ID: 5294799912 Enrollment ID: I20041112000800 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gaylen M Kelton |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1689651721 PECOS PAC ID: 0042276362 Enrollment ID: I20041208000081 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mary Elizabeth Schueth |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1558322123 PECOS PAC ID: 1052378650 Enrollment ID: I20041215000656 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel S Smith |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1992762066 PECOS PAC ID: 8224096441 Enrollment ID: I20041220001020 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Aaron E Carroll |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1013943125 PECOS PAC ID: 3779533518 Enrollment ID: I20050128000515 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Chris P Karras |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1396710513 PECOS PAC ID: 0941254965 Enrollment ID: I20050311000349 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sagi V Mathew |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1720044217 PECOS PAC ID: 9234117953 Enrollment ID: I20050323000671 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David Michael Blackwell |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1104903111 PECOS PAC ID: 8921055708 Enrollment ID: I20050404000872 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Robert Marquez De Las Alas |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1386688182 PECOS PAC ID: 7214974724 Enrollment ID: I20050414001275 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Theresa L Greco |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1356318240 PECOS PAC ID: 4789625146 Enrollment ID: I20050516000649 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jeffrey A Kons |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1588629133 PECOS PAC ID: 3173565074 Enrollment ID: I20050601000202 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel J Fagan |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1831156330 PECOS PAC ID: 8022050988 Enrollment ID: I20050601000731 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Cami S Barger Jones |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1467426429 PECOS PAC ID: 3870536485 Enrollment ID: I20050606000249 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | William A Heisel |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1508819772 PECOS PAC ID: 5092750968 Enrollment ID: I20050621001211 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kirk D Perry |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1609840578 PECOS PAC ID: 5991740730 Enrollment ID: I20050622001195 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Valerie A Purvin |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1811902695 PECOS PAC ID: 7719923713 Enrollment ID: I20050630000337 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Katharina M Weber |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1487694113 PECOS PAC ID: 1850337304 Enrollment ID: I20050706000622 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shashank J Dave |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1447214440 PECOS PAC ID: 2860421690 Enrollment ID: I20050811000441 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carleigh Elissa Wilson |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1831151059 PECOS PAC ID: 6204890486 Enrollment ID: I20050812000432 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ashwin Narasimhan |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1548241912 PECOS PAC ID: 8426088659 Enrollment ID: I20050817000880 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sarah Jeannette Mckenna |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1033167101 PECOS PAC ID: 9032144837 Enrollment ID: I20050929001175 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mitchell D Krathwohl |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1447225818 PECOS PAC ID: 0749208643 Enrollment ID: I20051110000131 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Timothy Justin Broach |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1508822792 PECOS PAC ID: 5092734442 Enrollment ID: I20051115001083 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bryan R Mayol |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1669484333 PECOS PAC ID: 0840219788 Enrollment ID: I20051121000306 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Don-john Summerlin |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1114975018 PECOS PAC ID: 3577572965 Enrollment ID: I20060412000547 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rosalia Misseri |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1538127501 PECOS PAC ID: 2365412350 Enrollment ID: I20060721000140 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kishan B Patel |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1265455836 PECOS PAC ID: 2264437961 Enrollment ID: I20061003000153 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Alejandro A Vega |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1316907819 PECOS PAC ID: 7719982339 Enrollment ID: I20061003000326 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jennifer R Hur |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1740212448 PECOS PAC ID: 1557344264 Enrollment ID: I20061011000146 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael A Rawlings |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1851332100 PECOS PAC ID: 9032118534 Enrollment ID: I20061211000442 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Aaron Afshin Cohen-gadol |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1215962279 PECOS PAC ID: 0244260909 Enrollment ID: I20061215000099 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Alicyn D Robb |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1740387109 PECOS PAC ID: 5496858193 Enrollment ID: I20070319000317 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Laura Stover Price |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1396784864 PECOS PAC ID: 4284730284 Enrollment ID: I20070508000687 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jane E Wilson |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1659375335 PECOS PAC ID: 3173620499 Enrollment ID: I20070522000376 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sunil Jayant Juthani |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1922058684 PECOS PAC ID: 2567560402 Enrollment ID: I20070531000216 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rosen Dimitrov |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1841273638 PECOS PAC ID: 0446224844 Enrollment ID: I20070604000506 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Steven D Hill |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1598716458 PECOS PAC ID: 9830297407 Enrollment ID: I20070605000373 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michelle M Haweit |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1376653014 PECOS PAC ID: 2860590015 Enrollment ID: I20070612000180 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Louis E Cantor |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1487655783 PECOS PAC ID: 7618075813 Enrollment ID: I20070612000662 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Darla J Gowan |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1538372792 PECOS PAC ID: 8820197825 Enrollment ID: I20070615000193 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jeffrey J Nace |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1619984556 PECOS PAC ID: 6901905827 Enrollment ID: I20070619000066 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jeffrey Richard Ihlendorf |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1205848728 PECOS PAC ID: 8921108614 Enrollment ID: I20070710000883 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Alicia Rene Yilmaz |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1699888305 PECOS PAC ID: 3779683479 Enrollment ID: I20070711000016 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Patrick E Kelley |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1235180373 PECOS PAC ID: 5799876645 Enrollment ID: I20070807000079 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kathryn M Haider |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1144421041 PECOS PAC ID: 0749372977 Enrollment ID: I20070817000383 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tamika Shawnice Dawson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1942400734 PECOS PAC ID: 0143312249 Enrollment ID: I20070822000026 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Yasser A Mohamed |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1366649626 PECOS PAC ID: 1759473739 Enrollment ID: I20070822000841 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Hui Bae H Lee |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1801874599 PECOS PAC ID: 6507833589 Enrollment ID: I20070831000007 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tracy P Murray |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1942494307 PECOS PAC ID: 0941395248 Enrollment ID: I20071002000254 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Peter M Turlo |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1093785628 PECOS PAC ID: 8729173596 Enrollment ID: I20071009000501 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kevin D Neese |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1699710319 PECOS PAC ID: 6800867383 Enrollment ID: I20071016000210 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Theresa M Rohr-kirchgraber |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1245258599 PECOS PAC ID: 2365416260 Enrollment ID: I20071026000091 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | John R Mcnary |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1316143092 PECOS PAC ID: 3577652452 Enrollment ID: I20071129000482 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Devonne A Elkins |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1619913001 PECOS PAC ID: 1759385180 Enrollment ID: I20080318000402 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Muhammad T Idrees |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1285848671 PECOS PAC ID: 2365538634 Enrollment ID: I20080414000475 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Helen E Michael |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1508819616 PECOS PAC ID: 2163500919 Enrollment ID: I20080421000221 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Simon J Warren |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1407828684 PECOS PAC ID: 4587680848 Enrollment ID: I20080429000206 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kendra L Rininger |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528264322 PECOS PAC ID: 5092893263 Enrollment ID: I20080429000425 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rong Fan |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1669648408 PECOS PAC ID: 7517038474 Enrollment ID: I20080619000673 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | James C Miller |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1083884696 PECOS PAC ID: 5890867246 Enrollment ID: I20080701000168 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mehdi Nassiri |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1538335377 PECOS PAC ID: 9638241920 Enrollment ID: I20080701000549 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kelly L Paul |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1588839856 PECOS PAC ID: 8325110091 Enrollment ID: I20080712000118 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Glynnis L Thatch |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1366466492 PECOS PAC ID: 7214001932 Enrollment ID: I20080729000754 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ruben H Hernandez Mondragon |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1013181387 PECOS PAC ID: 0547334724 Enrollment ID: I20080806000326 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Aaron M Leary |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1477710903 PECOS PAC ID: 5890869747 Enrollment ID: I20080811000507 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | James M Lohman |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1548382104 PECOS PAC ID: 6901973643 Enrollment ID: I20080923000416 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael G Tuano |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1194781450 PECOS PAC ID: 0547343246 Enrollment ID: I20081008000019 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tabassum I Parkar |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1205015898 PECOS PAC ID: 8325116098 Enrollment ID: I20081008000110 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Timothy A Masterson |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1528227923 PECOS PAC ID: 8921167321 Enrollment ID: I20081029000899 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stacy L Wade |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770742462 PECOS PAC ID: 7911066196 Enrollment ID: I20081103000280 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jesse Spear |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1447339684 PECOS PAC ID: 6204920416 Enrollment ID: I20081209000690 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jeremy G Remus |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1467401794 PECOS PAC ID: 9537193602 Enrollment ID: I20081218000162 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Yara P Catoira-boyle |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1396746459 PECOS PAC ID: 3577625763 Enrollment ID: I20081223000034 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Richard C Rink |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1720074149 PECOS PAC ID: 4486624418 Enrollment ID: I20090112000436 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David P Pletzer |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1467426239 PECOS PAC ID: 7012989874 Enrollment ID: I20090324000061 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael T Johnson |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1083720817 PECOS PAC ID: 4284791856 Enrollment ID: I20090325000787 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniela A Lobo |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1720241144 PECOS PAC ID: 8123185501 Enrollment ID: I20090330000619 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Candice R Hamilton |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1063507374 PECOS PAC ID: 2860543444 Enrollment ID: I20090622000275 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David Fryman |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1750347993 PECOS PAC ID: 6709884869 Enrollment ID: I20090710000481 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Zandra S Dhue |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1013177575 PECOS PAC ID: 0547312936 Enrollment ID: I20090715000744 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | John D Baldea |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1831246347 PECOS PAC ID: 1850445255 Enrollment ID: I20090819000854 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Oscar W Cummings |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1235181918 PECOS PAC ID: 6406900786 Enrollment ID: I20090820000718 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Neetu Mahendraker |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1184899502 PECOS PAC ID: 2668526849 Enrollment ID: I20090822000125 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Haihong Mao |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1023225901 PECOS PAC ID: 6507911641 Enrollment ID: I20090826000225 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Charles R Powell |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1013125871 PECOS PAC ID: 3678643293 Enrollment ID: I20090828000225 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Seth D Rinderknecht |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1154591220 PECOS PAC ID: 7618022435 Enrollment ID: I20090831000628 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Richard W Pearson |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1386731875 PECOS PAC ID: 7214821529 Enrollment ID: I20090930000646 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Adam W Brazus |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1144286311 PECOS PAC ID: 8729125158 Enrollment ID: I20091016000375 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Donna J Purviance |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013240597 PECOS PAC ID: 4688711559 Enrollment ID: I20091026000387 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stephen R Klapper |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1316910607 PECOS PAC ID: 8123166857 Enrollment ID: I20091117000393 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mushkbar J Khan |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1013170430 PECOS PAC ID: 3274672290 Enrollment ID: I20091204000468 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Angela T Carbone |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1184688186 PECOS PAC ID: 8820137516 Enrollment ID: I20091210000086 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Flora Hammond |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1306860358 PECOS PAC ID: 0143268342 Enrollment ID: I20091231000030 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Natasha Singh |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1528157732 PECOS PAC ID: 2860585932 Enrollment ID: I20100111000172 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Eric W Waldo |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1356501514 PECOS PAC ID: 9830231414 Enrollment ID: I20100120000279 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nathan D Prahlow |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1770547788 PECOS PAC ID: 3577607563 Enrollment ID: I20100215000050 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Scott A Shapiro |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1790788321 PECOS PAC ID: 6103960778 Enrollment ID: I20100219000542 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kirsten E Kaisner-duncan |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1114984572 PECOS PAC ID: 3870637259 Enrollment ID: I20100223000735 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gail H Vance |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1649236217 PECOS PAC ID: 4688719883 Enrollment ID: I20100226000248 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Wilfredo Torres Martinez |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1487610051 PECOS PAC ID: 4789729997 Enrollment ID: I20100226000357 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mitesh V Shah |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1851394340 PECOS PAC ID: 8325183551 Enrollment ID: I20100226000602 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Her-juing Wu |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1700983277 PECOS PAC ID: 0840184156 Enrollment ID: I20100311000006 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gail Stotsky |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1215976907 PECOS PAC ID: 9931234184 Enrollment ID: I20100313000025 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brian R Leon |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1356309587 PECOS PAC ID: 4688709702 Enrollment ID: I20100315000821 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Anthony N Akosa |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1295791200 PECOS PAC ID: 5294860326 Enrollment ID: I20100315000865 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel W Belcher |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1447216932 PECOS PAC ID: 0345375077 Enrollment ID: I20100318000911 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mark D Bruns |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1740248962 PECOS PAC ID: 0749315356 Enrollment ID: I20100322000694 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael Busha |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1871660472 PECOS PAC ID: 9739075276 Enrollment ID: I20100325000216 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gregory C Kiray |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1639136906 PECOS PAC ID: 8729114921 Enrollment ID: I20100326000625 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Deanna R Willis |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1891753778 PECOS PAC ID: 3779619911 Enrollment ID: I20100327000000 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Susan G Kiray |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1205943958 PECOS PAC ID: 2860528007 Enrollment ID: I20100327000010 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel J Robinson |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1457355307 PECOS PAC ID: 3678555240 Enrollment ID: I20100405000192 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Thomas R Marshall |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1932153947 PECOS PAC ID: 2466588041 Enrollment ID: I20100407000783 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Leeandrea Jm Sloan |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1730137563 PECOS PAC ID: 7911033444 Enrollment ID: I20100409000086 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rhonda Jeanne Eubanks |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1235177338 PECOS PAC ID: 6204963432 Enrollment ID: I20100420000956 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Eric Andrew Bannec |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1093710881 PECOS PAC ID: 0244284552 Enrollment ID: I20100422001080 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Thomas A Kocoshis |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1467565838 PECOS PAC ID: 0042104358 Enrollment ID: I20100427000788 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Elliott A Yolles |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1326038654 PECOS PAC ID: 8820124340 Enrollment ID: I20100429000544 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rachael S Bowles |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1295793412 PECOS PAC ID: 3577691898 Enrollment ID: I20100506001011 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David H Porter |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1558317909 PECOS PAC ID: 5294863510 Enrollment ID: I20100506001032 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Thomas C Witt |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1801899422 PECOS PAC ID: 5092841833 Enrollment ID: I20100513000708 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mary R Brunner |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1871535567 PECOS PAC ID: 8628108198 Enrollment ID: I20100609000595 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Belinda J Watts |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1184665887 PECOS PAC ID: 0345370854 Enrollment ID: I20100610000092 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Denise Ash |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1023277399 PECOS PAC ID: 4385773910 Enrollment ID: I20100610000197 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | John F Schaefer |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1932142908 PECOS PAC ID: 9032249560 Enrollment ID: I20100610000263 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Deborah S Kinnamon |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1093759102 PECOS PAC ID: 4082744511 Enrollment ID: I20100610000325 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Elisabeth D Kline |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1205879293 PECOS PAC ID: 4880724319 Enrollment ID: I20100610000351 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jerry L Rushton |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1124086434 PECOS PAC ID: 8022148212 Enrollment ID: I20100615000328 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kathryn B Johnston |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1912100041 PECOS PAC ID: 6507996626 Enrollment ID: I20100615000834 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | James Bohney |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1083671002 PECOS PAC ID: 8921138983 Enrollment ID: I20100617000649 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Karen M Wheeler |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1073559290 PECOS PAC ID: 7517098973 Enrollment ID: I20100629000101 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ann D Zerr |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1558304469 PECOS PAC ID: 3678604063 Enrollment ID: I20100629000382 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Xiao-ming Yin |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1588630818 PECOS PAC ID: 5193761062 Enrollment ID: I20100712000644 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | John F Fitzgerald |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1457318719 PECOS PAC ID: 7517879158 Enrollment ID: I20100722000501 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Deshini A Moonesinghe |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1780882449 PECOS PAC ID: 6709918006 Enrollment ID: I20100722000547 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Patricia A Treadwell |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1508892613 PECOS PAC ID: 3577696319 Enrollment ID: I20100730000856 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Broderick J Rhyant |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1083662134 PECOS PAC ID: 7517090160 Enrollment ID: I20100803000272 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Chandru P Sundaram |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1609861384 PECOS PAC ID: 1850424060 Enrollment ID: I20100809000207 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jason T Cadwallader |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1942467469 PECOS PAC ID: 9335273366 Enrollment ID: I20100812001005 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Laurie Ackerman |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1477667426 PECOS PAC ID: 0345209821 Enrollment ID: I20100820001047 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Yeuk Ting Bonnie Wong |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1538328075 PECOS PAC ID: 3072637891 Enrollment ID: I20100901000083 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Heather A Smith |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1831392935 PECOS PAC ID: 8729102306 Enrollment ID: I20100903000081 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jennifer Lauren Eikenberry |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1891998027 PECOS PAC ID: 1254455843 Enrollment ID: I20100903000241 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amanda J Gosch |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1033370267 PECOS PAC ID: 3476678657 Enrollment ID: I20100910000835 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gautam Phookan |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1093750978 PECOS PAC ID: 9335264597 Enrollment ID: I20100913000428 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel William Voegele |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1245271691 PECOS PAC ID: 0042335929 Enrollment ID: I20100915000927 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael Oscar Koch |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1821084252 PECOS PAC ID: 1153391172 Enrollment ID: I20100917000749 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nicole K Greives |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972818938 PECOS PAC ID: 8527250083 Enrollment ID: I20101004000361 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Scott A Robbins |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1699906321 PECOS PAC ID: 4688866841 Enrollment ID: I20101006000235 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Melissa Craig |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1043527856 PECOS PAC ID: 9335331040 Enrollment ID: I20101012001238 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Boguslaw I Uchman |
---|---|
Provider Type | Practitioner - Nuclear Medicine |
Provider Identifiers | NPI Number: 1124023387 PECOS PAC ID: 1153459037 Enrollment ID: I20101019000431 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gloria Fritsch |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1235395534 PECOS PAC ID: 0840483889 Enrollment ID: I20101021001348 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Naveen Rajoli |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1306029608 PECOS PAC ID: 7810181625 Enrollment ID: I20101104001324 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jessie M White |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1194700765 PECOS PAC ID: 8527256114 Enrollment ID: I20101227000141 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Dorota Szczepaniak |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1972597649 PECOS PAC ID: 0547459554 Enrollment ID: I20110106000449 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | April L Graves |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1558672592 PECOS PAC ID: 1153510011 Enrollment ID: I20110106001155 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Melissa M Pearson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1851548341 PECOS PAC ID: 8527257211 Enrollment ID: I20110111000948 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Syed J Sher |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1174694665 PECOS PAC ID: 4486617289 Enrollment ID: I20110208000452 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jennifer N Weida |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1689833915 PECOS PAC ID: 1658552112 Enrollment ID: I20110217000090 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Philip C Ferguson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1093770265 PECOS PAC ID: 2365625506 Enrollment ID: I20110324000707 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sharron P Grannis |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1194773267 PECOS PAC ID: 6901089150 Enrollment ID: I20110324000719 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kurt A Patterson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1902863533 PECOS PAC ID: 6204019458 Enrollment ID: I20110324000800 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Richard H Bernhardt |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1487850988 PECOS PAC ID: 3870770415 Enrollment ID: I20110607000559 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shaoxiong Chen |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1144541228 PECOS PAC ID: 9739366295 Enrollment ID: I20110609000240 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jiehao Zhou |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1184858276 PECOS PAC ID: 8921285495 Enrollment ID: I20110609000356 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Zainab J Sher |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1093878647 PECOS PAC ID: 6103812664 Enrollment ID: I20110615000166 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Eric Djenge |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1437322567 PECOS PAC ID: 8820276538 Enrollment ID: I20110629000035 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Catherine E Thompson |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1699743690 PECOS PAC ID: 9830198118 Enrollment ID: I20110715000315 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Marzena W Muller |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1518167410 PECOS PAC ID: 6103916879 Enrollment ID: I20110720000155 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shanxiang Zhang |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1750545265 PECOS PAC ID: 0244409696 Enrollment ID: I20110802000082 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Anand P Patel |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1346361904 PECOS PAC ID: 7113116112 Enrollment ID: I20110810000406 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Zhanna Albany |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1861654220 PECOS PAC ID: 7012186935 Enrollment ID: I20110811000060 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Christine C. Groves |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1457527780 PECOS PAC ID: 5991974610 Enrollment ID: I20110812000447 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Naomi C Lightburn |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1104087311 PECOS PAC ID: 2769651207 Enrollment ID: I20110817000893 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jingmei Lin |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1588787147 PECOS PAC ID: 8325218514 Enrollment ID: I20110825000457 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bhuvaneswari Burugapalli |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1518127695 PECOS PAC ID: 4981874039 Enrollment ID: I20110826000453 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michelle K Zimmerman |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1497077853 PECOS PAC ID: 1658541495 Enrollment ID: I20110902000400 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | April A Jones |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1679860993 PECOS PAC ID: 0143490870 Enrollment ID: I20110907000863 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Meagan B Oneill |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1841452216 PECOS PAC ID: 9133390529 Enrollment ID: I20110915000028 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Margaret Elaine Southwood |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1437160413 PECOS PAC ID: 0941471692 Enrollment ID: I20110929000133 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lynette Smith-caillouet |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1871680199 PECOS PAC ID: 8921135690 Enrollment ID: I20111010000561 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Robert E Emerson |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1487611604 PECOS PAC ID: 2163694480 Enrollment ID: I20111011000290 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jose M Bonnin |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1366409120 PECOS PAC ID: 2163694498 Enrollment ID: I20111011000422 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Thomas M Ulbright |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1376500918 PECOS PAC ID: 8325210669 Enrollment ID: I20111011000446 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Liang Cheng |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1528025301 PECOS PAC ID: 4486826724 Enrollment ID: I20111011000497 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Paul M Musto |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1568429603 PECOS PAC ID: 0941472138 Enrollment ID: I20111012000373 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jaci R Glass |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1326320656 PECOS PAC ID: 9436321569 Enrollment ID: I20111013000124 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lisbeth G Larsson |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1083667711 PECOS PAC ID: 8729250881 Enrollment ID: I20111013000504 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Raymond L Konger |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1760433379 PECOS PAC ID: 5193997906 Enrollment ID: I20111020000038 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carrie L Phillips |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1720045875 PECOS PAC ID: 3274705090 Enrollment ID: I20111020000057 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Harvey M Cramer |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1023060712 PECOS PAC ID: 6103098975 Enrollment ID: I20111020000746 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Diana P Summanwar |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1184887887 PECOS PAC ID: 7315110905 Enrollment ID: I20111026000615 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Romil Saxena |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1629035399 PECOS PAC ID: 3072786185 Enrollment ID: I20111107000374 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Magdalena B Czader |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1720045503 PECOS PAC ID: 4385817394 Enrollment ID: I20111107000582 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sunil Badve |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1699732453 PECOS PAC ID: 6800069865 Enrollment ID: I20111108000224 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Darrell Wudunn |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1295736536 PECOS PAC ID: 9436257649 Enrollment ID: I20111115000392 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Chi Wah Yung |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1295736544 PECOS PAC ID: 1254439466 Enrollment ID: I20111115000777 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David Plager |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1922009083 PECOS PAC ID: 7416926258 Enrollment ID: I20111201000166 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Javier Sevilla |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1023076775 PECOS PAC ID: 7911172804 Enrollment ID: I20111205000197 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kevin Bernard Gebke |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1316903511 PECOS PAC ID: 5597775429 Enrollment ID: I20111215000842 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Debra Spector Boyce |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1932109881 PECOS PAC ID: 6901964287 Enrollment ID: I20120109000304 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kevin L Jones |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1558398024 PECOS PAC ID: 9830366475 Enrollment ID: I20120123000079 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Joey P Sum |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1437350493 PECOS PAC ID: 1052404449 Enrollment ID: I20120223000658 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel E Neely |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1144221326 PECOS PAC ID: 8729246210 Enrollment ID: I20120301000487 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Maria Cuda |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1316946320 PECOS PAC ID: 4789671710 Enrollment ID: I20120307000006 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jamie L Bradbury |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1861659450 PECOS PAC ID: 1557487030 Enrollment ID: I20120315000164 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Marcie K Judge |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558521849 PECOS PAC ID: 6103088125 Enrollment ID: I20120508000471 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kavitha Subramoney |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1194958033 PECOS PAC ID: 8729241054 Enrollment ID: I20120523000421 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Noaman F Siddiqi |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1124294749 PECOS PAC ID: 7618157470 Enrollment ID: I20120530000010 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael Peter Sinnott |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1477720522 PECOS PAC ID: 8820252216 Enrollment ID: I20120615000011 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nicole R Phillips |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1386870772 PECOS PAC ID: 8426212515 Enrollment ID: I20120621000553 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mackenzie E Lupov |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1336371509 PECOS PAC ID: 2769647791 Enrollment ID: I20120626000063 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Benjamin Whittam |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1508913328 PECOS PAC ID: 1052576618 Enrollment ID: I20120705000026 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Debasmita Mohapatra |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1558625491 PECOS PAC ID: 2668637836 Enrollment ID: I20120713000420 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Melissa D Lah |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1962607820 PECOS PAC ID: 2264698356 Enrollment ID: I20120717000538 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rajnish Khillan |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1043541949 PECOS PAC ID: 3476719113 Enrollment ID: I20120724000575 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mallery R Neff |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1528387628 PECOS PAC ID: 2860648078 Enrollment ID: I20120803000217 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Dara L Sander |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1457611584 PECOS PAC ID: 1254587330 Enrollment ID: I20120806000089 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nishi Dave |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1821288275 PECOS PAC ID: 5294983094 Enrollment ID: I20120920000379 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Raime C Blattner |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679829055 PECOS PAC ID: 5193975936 Enrollment ID: I20121101000202 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Andrea L Moser |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770831810 PECOS PAC ID: 2668624529 Enrollment ID: I20121129000173 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amy G Lawrence |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1063763332 PECOS PAC ID: 9032361548 Enrollment ID: I20121208000005 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sara E Cook |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1588823694 PECOS PAC ID: 6709038219 Enrollment ID: I20121210000017 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jacqueline M Nonweiler- Parr |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1508036633 PECOS PAC ID: 1759428170 Enrollment ID: I20130102000172 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shawn A Tinkham |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1659627891 PECOS PAC ID: 0042465197 Enrollment ID: I20130221000423 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Susan K Adkins |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1144577818 PECOS PAC ID: 6608021555 Enrollment ID: I20130227000193 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David J Rizk |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1558529198 PECOS PAC ID: 1052451218 Enrollment ID: I20130306000600 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Won Sun Lee |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1720007412 PECOS PAC ID: 9133258254 Enrollment ID: I20130429000274 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bryan H Schmitt |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1649235466 PECOS PAC ID: 2567633068 Enrollment ID: I20130501000580 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Donna L O Daniel |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1811237415 PECOS PAC ID: 9234377698 Enrollment ID: I20130524000629 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ehab M Wanas |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1114151669 PECOS PAC ID: 9335397132 Enrollment ID: I20130805000260 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael Peregrim |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1790001303 PECOS PAC ID: 7810139318 Enrollment ID: I20130813000584 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Whitney Michelle Pratt |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1083849335 PECOS PAC ID: 3678712254 Enrollment ID: I20130828000735 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Chen Zhang |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1184887515 PECOS PAC ID: 2062678667 Enrollment ID: I20130830000490 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brock D Mcmillen |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1952629644 PECOS PAC ID: 4082850862 Enrollment ID: I20130906000444 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jonathan T Shirazi |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1124330857 PECOS PAC ID: 0244470326 Enrollment ID: I20130906000452 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stephen J Hartsock |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1114938453 PECOS PAC ID: 7214171362 Enrollment ID: I20130911000804 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mohamed H Morad |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1730481870 PECOS PAC ID: 3779723564 Enrollment ID: I20130916000098 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jessica J Kluetz |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1235367616 PECOS PAC ID: 4981838109 Enrollment ID: I20131001000509 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Matthew J Kuhar |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1699934547 PECOS PAC ID: 6608069679 Enrollment ID: I20131016000958 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kelly C Cary |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1073770657 PECOS PAC ID: 7810166113 Enrollment ID: I20131017001915 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Clinton David Bahler |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1780842153 PECOS PAC ID: 9436390986 Enrollment ID: I20131023000456 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rebecca O'bryan |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1295900652 PECOS PAC ID: 5395992531 Enrollment ID: I20131102000145 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Konrad M Szymanski |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1750646691 PECOS PAC ID: 1456590264 Enrollment ID: I20131111001513 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bharat Ns Sastry |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1093963068 PECOS PAC ID: 1557418027 Enrollment ID: I20131112002046 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Latifat A Oyekola |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1376756684 PECOS PAC ID: 2860557352 Enrollment ID: I20131125000947 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Erika A Dunn |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1376979245 PECOS PAC ID: 6608004221 Enrollment ID: I20140106000347 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Barbara D Evens |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679906010 PECOS PAC ID: 1951539261 Enrollment ID: I20140113001556 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Melissa A Young |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1104191402 PECOS PAC ID: 5092944363 Enrollment ID: I20140207000299 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kevin Allen Swartz |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1669546404 PECOS PAC ID: 1456420454 Enrollment ID: I20140210000900 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Candice D Moad |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1942641840 PECOS PAC ID: 8527299098 Enrollment ID: I20140326000846 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nusiratu T Cosby |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1508289422 PECOS PAC ID: 8123259363 Enrollment ID: I20140401000908 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tessa Cecile Palmer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1639594773 PECOS PAC ID: 7113159583 Enrollment ID: I20140417000878 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jeffrey Paul Williams |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1780661074 PECOS PAC ID: 1052492097 Enrollment ID: I20140505000111 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Henry Robert Knouse |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1275824500 PECOS PAC ID: 8123265139 Enrollment ID: I20140508001262 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Danielle N Wiese |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1447559802 PECOS PAC ID: 5092939496 Enrollment ID: I20140604001428 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Danielle M Erney |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1568690519 PECOS PAC ID: 7113142548 Enrollment ID: I20140627000427 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Christopher M Kniese |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1962796102 PECOS PAC ID: 6204079239 Enrollment ID: I20140703000252 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nisha S Kheradiya |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1891937819 PECOS PAC ID: 4688899370 Enrollment ID: I20140714002122 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Arnold F Henry |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1942511472 PECOS PAC ID: 6800025321 Enrollment ID: I20140716000749 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel J Ordaz |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1437474988 PECOS PAC ID: 6103059100 Enrollment ID: I20140717000609 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Allison A Pernic |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1497070957 PECOS PAC ID: 4688890148 Enrollment ID: I20140718002146 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Robert Michael Schrock |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1932544533 PECOS PAC ID: 6901022086 Enrollment ID: I20140725000961 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stephanie M. Ware |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1174555999 PECOS PAC ID: 3577511831 Enrollment ID: I20140804000440 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Anshu Sidana |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1659662872 PECOS PAC ID: 4587801469 Enrollment ID: I20140814000758 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Christa N Robertson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1609282946 PECOS PAC ID: 4082832795 Enrollment ID: I20140821001201 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Chadi Saifan |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1740450477 PECOS PAC ID: 1052487923 Enrollment ID: I20140916001233 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ashley R Lawrence |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1629239314 PECOS PAC ID: 2769601103 Enrollment ID: I20140916002522 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Hongmei Yang |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1083840698 PECOS PAC ID: 3971757428 Enrollment ID: I20140924001420 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tara L Bouton |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518392026 PECOS PAC ID: 5890923072 Enrollment ID: I20140929001639 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Linda L Boone |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1134529753 PECOS PAC ID: 0446472617 Enrollment ID: I20141104001870 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lora Meyer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1306039433 PECOS PAC ID: 0941523310 Enrollment ID: I20141217000127 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nathanial Ray Chumley |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1316218571 PECOS PAC ID: 8820234396 Enrollment ID: I20150114001856 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jesse J Savage |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1881828085 PECOS PAC ID: 9436478989 Enrollment ID: I20150505000293 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Garrett J Jackson |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1336381631 PECOS PAC ID: 1557680006 Enrollment ID: I20150505000563 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Zhi Xu |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1235499989 PECOS PAC ID: 0648590547 Enrollment ID: I20150515001692 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ausama M Ismail |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1710245626 PECOS PAC ID: 4284870064 Enrollment ID: I20150515001800 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Drew A Kepple |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1104117167 PECOS PAC ID: 9739329814 Enrollment ID: I20150528001832 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Omer S Al-buoshkor |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1144586934 PECOS PAC ID: 7719125814 Enrollment ID: I20150604002827 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Eric W Han |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1841565942 PECOS PAC ID: 8123349446 Enrollment ID: I20150611001046 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Roy G Henderson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1861426694 PECOS PAC ID: 3173663689 Enrollment ID: I20150611001103 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brian Christopher Middleton |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1427285196 PECOS PAC ID: 4284886664 Enrollment ID: I20150616000762 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Charline S Boente |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1114211505 PECOS PAC ID: 9931410511 Enrollment ID: I20150623002845 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jonathan D Moulder |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1831459890 PECOS PAC ID: 4082850557 Enrollment ID: I20150706001828 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Alicia S Almeida Ponce |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1194089409 PECOS PAC ID: 4688810153 Enrollment ID: I20150708002134 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kimbre V Zahn |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1659662203 PECOS PAC ID: 1052542560 Enrollment ID: I20150715001039 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sheryl D Katta Charles |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1871881367 PECOS PAC ID: 5597078675 Enrollment ID: I20150717002378 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Samantha L Polster |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1790162915 PECOS PAC ID: 7012221435 Enrollment ID: I20150729009417 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Zhipeng Zhang |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1720366313 PECOS PAC ID: 7618281049 Enrollment ID: I20150729009952 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jean M Mensz |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1134407513 PECOS PAC ID: 3072827427 Enrollment ID: I20150730010828 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mustafa Hyder |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1275821563 PECOS PAC ID: 2163736273 Enrollment ID: I20150803003028 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Glenda L Ramirez |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1851603658 PECOS PAC ID: 1557592276 Enrollment ID: I20150908001221 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shobha Shahani |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1679824700 PECOS PAC ID: 0244546125 Enrollment ID: I20150909000684 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Claudia J Brock |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1225326606 PECOS PAC ID: 3476860875 Enrollment ID: I20150917001114 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Marilyn A Jones |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1003290974 PECOS PAC ID: 2163739244 Enrollment ID: I20150922002824 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stephen M Jovonovich |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1457594145 PECOS PAC ID: 8628388758 Enrollment ID: I20151102002129 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Desirae M Hyde |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568834190 PECOS PAC ID: 8325358740 Enrollment ID: I20151113001299 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Marcela Chacon Enciso |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1336439272 PECOS PAC ID: 9739328774 Enrollment ID: I20151120002151 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Neshahthari Wijeyakuhan |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1962717348 PECOS PAC ID: 3577707744 Enrollment ID: I20151202000829 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Enoch B Kassa |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1083980858 PECOS PAC ID: 6901039601 Enrollment ID: I20151218000181 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nguyet Le |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1528222866 PECOS PAC ID: 3971790973 Enrollment ID: I20160107002625 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Devina Prasad |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1881921344 PECOS PAC ID: 5294905063 Enrollment ID: I20160126001437 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Pamela M Breedlove |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1366834293 PECOS PAC ID: 3274837679 Enrollment ID: I20160204002039 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Aditya Ahlawat |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1427496322 PECOS PAC ID: 4385868751 Enrollment ID: I20160224001459 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rebecca E Pullyard |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124487145 PECOS PAC ID: 0840597092 Enrollment ID: I20160401001459 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Leticia Nicolle Nunez De Perez |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1548665953 PECOS PAC ID: 1850690306 Enrollment ID: I20160504001859 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Aaron G Watters |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1811288152 PECOS PAC ID: 8325286230 Enrollment ID: I20160519002161 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Julie Chow |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1891016838 PECOS PAC ID: 4082904941 Enrollment ID: I20160606000269 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kris A Homb |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1366767006 PECOS PAC ID: 1759508393 Enrollment ID: I20160606000353 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Olivia J Park |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1669761748 PECOS PAC ID: 7810287786 Enrollment ID: I20160606000564 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kyle Littell |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1164782348 PECOS PAC ID: 4688815764 Enrollment ID: I20160613002398 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ryan K Alexander |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1184063331 PECOS PAC ID: 8527362607 Enrollment ID: I20160613002447 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Unknown Sanna |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1093142978 PECOS PAC ID: 7416248828 Enrollment ID: I20160615000703 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Simranjit Singh |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1598192650 PECOS PAC ID: 5496046856 Enrollment ID: I20160615002261 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Denis Jusufbegovic |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1952544975 PECOS PAC ID: 7416263306 Enrollment ID: I20160616001321 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Christopher M Dipiro |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1285968149 PECOS PAC ID: 1355525296 Enrollment ID: I20160621000207 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shaohui Liu |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1881980779 PECOS PAC ID: 1658683180 Enrollment ID: I20160621001768 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Catherine Moya Krumenacker |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1922442458 PECOS PAC ID: 6901040286 Enrollment ID: I20160622000378 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Alnee L Gadberry |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1578925103 PECOS PAC ID: 3779874565 Enrollment ID: I20160627000499 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amy Elizabeth Krambeck |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1265419006 PECOS PAC ID: 4486704657 Enrollment ID: I20160629001965 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Simit M Doshi |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1538580253 PECOS PAC ID: 7719285451 Enrollment ID: I20160708000470 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bryan M Leber |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1598100273 PECOS PAC ID: 1153555057 Enrollment ID: I20160708000624 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lara E Darling |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1174961528 PECOS PAC ID: 9537393673 Enrollment ID: I20160708001072 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Conan V Chittick |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1396004404 PECOS PAC ID: 9830335306 Enrollment ID: I20160715000662 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David Stockwell |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1861664682 PECOS PAC ID: 2769775428 Enrollment ID: I20160719001037 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Marcelino E Rivera |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1538454210 PECOS PAC ID: 3274780739 Enrollment ID: I20160725000841 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Matthew W Wolenski |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1922367309 PECOS PAC ID: 9537305008 Enrollment ID: I20160727000182 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Beth Ann Shelton |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1306075510 PECOS PAC ID: 1658513569 Enrollment ID: I20160729000847 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carrie J Osborne |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871956813 PECOS PAC ID: 6305130055 Enrollment ID: I20160803002334 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Katherine A Ahlfeld |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1730553447 PECOS PAC ID: 8729372883 Enrollment ID: I20160811002390 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Andrew H Jea |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1568662724 PECOS PAC ID: 3870676851 Enrollment ID: I20160815002102 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Katherine A Gray |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1396197950 PECOS PAC ID: 0143515924 Enrollment ID: I20160817002669 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Vinod Kumar |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1922435049 PECOS PAC ID: 5890080337 Enrollment ID: I20160823003023 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tanya Kezia Danielle Wilson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1366887564 PECOS PAC ID: 4486897360 Enrollment ID: I20160902001984 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Miguel R Escobar |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1376644856 PECOS PAC ID: 8022085968 Enrollment ID: I20160908000763 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Akaber Elkhamra |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1033373881 PECOS PAC ID: 0547419889 Enrollment ID: I20160914002949 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sam Valid |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1912318783 PECOS PAC ID: 1456668185 Enrollment ID: I20161004000048 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Alexander Vortmeyer |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1124265665 PECOS PAC ID: 2264596311 Enrollment ID: I20161004002405 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mary K Fuller-nave |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053867572 PECOS PAC ID: 3274821368 Enrollment ID: I20161005000366 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ahmed Khalid Alomari |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1962718494 PECOS PAC ID: 2062712623 Enrollment ID: I20161102000367 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Quinton R Sparrow |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1154663508 PECOS PAC ID: 2668750100 Enrollment ID: I20161103000985 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jennifer A Wilkins |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1760939771 PECOS PAC ID: 0244519148 Enrollment ID: I20161117000455 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Casaundra M Buning |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770916926 PECOS PAC ID: 7911141569 Enrollment ID: I20161202000323 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kelly A Smith |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1295988079 PECOS PAC ID: 8022269745 Enrollment ID: I20161228002263 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Khurram Shahzad |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1730446931 PECOS PAC ID: 8022327923 Enrollment ID: I20170118000379 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Emanuel L Pires |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1578754040 PECOS PAC ID: 7810082906 Enrollment ID: I20170130002459 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Melissa A Redden |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1215474572 PECOS PAC ID: 4284917584 Enrollment ID: I20170213000197 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Robert Wallace Byrn |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1700838307 PECOS PAC ID: 2365726940 Enrollment ID: I20170227000892 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Christopher L Emery |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1316999329 PECOS PAC ID: 3476631698 Enrollment ID: I20170307001506 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Afsa P Ali |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1710322862 PECOS PAC ID: 8820239775 Enrollment ID: I20170308000753 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Angela R Boyle |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1487191276 PECOS PAC ID: 7315221520 Enrollment ID: I20170308000862 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Hassan Mostafa |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1174939003 PECOS PAC ID: 1052537388 Enrollment ID: I20170405000315 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brittany K Cooper |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1508304551 PECOS PAC ID: 6002192879 Enrollment ID: I20170410001251 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jennifer Broaddus |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1689106056 PECOS PAC ID: 3274819479 Enrollment ID: I20170424000369 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rachel Peterson |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1780028134 PECOS PAC ID: 3779726757 Enrollment ID: I20170510001294 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Teela Dawn Crecelius |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1902210263 PECOS PAC ID: 3678798998 Enrollment ID: I20170510001363 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael Park |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1043659956 PECOS PAC ID: 3274828173 Enrollment ID: I20170511001063 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sidney H Allison |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1275893752 PECOS PAC ID: 2264709377 Enrollment ID: I20170522000066 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Benjamin Steven Randel |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1699112854 PECOS PAC ID: 4486894441 Enrollment ID: I20170525000455 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Muhammad M Haq |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1659790194 PECOS PAC ID: 6800164260 Enrollment ID: I20170608000975 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Farman Khan |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1396150686 PECOS PAC ID: 9335417609 Enrollment ID: I20170612000286 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Andrew Vincent Coccaro |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1861802779 PECOS PAC ID: 2860798816 Enrollment ID: I20170613000245 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Travis J Dams |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1154735702 PECOS PAC ID: 7113142084 Enrollment ID: I20170613000355 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shivani Bhatia Martin |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1558645366 PECOS PAC ID: 0749508265 Enrollment ID: I20170614000218 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Karl Erach Balsara |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1639490857 PECOS PAC ID: 9032419734 Enrollment ID: I20170615000371 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jeffrey S Raskin |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1740422898 PECOS PAC ID: 5698920411 Enrollment ID: I20170616000287 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Chintan N Prajapati |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1396162236 PECOS PAC ID: 5597985143 Enrollment ID: I20170616000938 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ellen M Klink |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1538507397 PECOS PAC ID: 5890937882 Enrollment ID: I20170621000792 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Matthea Rentea |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1376957845 PECOS PAC ID: 8729203732 Enrollment ID: I20170622002827 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amber J Perry |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1922535251 PECOS PAC ID: 2466720057 Enrollment ID: I20170623000564 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rebecca Renae Dunn |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1760829162 PECOS PAC ID: 3072747971 Enrollment ID: I20170626000692 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tivere Shemi |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1205188943 PECOS PAC ID: 0143440321 Enrollment ID: I20170705001836 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Pir K Ali |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1932467834 PECOS PAC ID: 6901108372 Enrollment ID: I20170705002473 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Yi Dong |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1104245687 PECOS PAC ID: 2668775073 Enrollment ID: I20170712000100 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kyle A Rahrig |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1205276144 PECOS PAC ID: 1153628441 Enrollment ID: I20170717000549 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ryan John Wise |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1932542842 PECOS PAC ID: 6608016126 Enrollment ID: I20170720000199 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Adam David Henry |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1679919294 PECOS PAC ID: 0244471761 Enrollment ID: I20170724002648 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brett H Graham |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1861572117 PECOS PAC ID: 9032005194 Enrollment ID: I20170725002301 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Porus Shah |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1447652953 PECOS PAC ID: 3375813173 Enrollment ID: I20170727001815 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Heather L Lutz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1023539004 PECOS PAC ID: 0244501922 Enrollment ID: I20170731001751 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shunhua Guo |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1548557853 PECOS PAC ID: 1658674015 Enrollment ID: I20170804000092 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Juan Carlos Venis |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1043623069 PECOS PAC ID: 8628295078 Enrollment ID: I20170807003704 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tony Y Ren |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1831503283 PECOS PAC ID: 5092930461 Enrollment ID: I20170808003616 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Matthew W George |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1154587921 PECOS PAC ID: 5991976367 Enrollment ID: I20170818001098 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Dan Robert Leimann |
---|---|
Provider Type | Practitioner - General Practice |
Provider Identifiers | NPI Number: 1306282066 PECOS PAC ID: 8527358431 Enrollment ID: I20170818001134 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mary K Eckerle |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1518300755 PECOS PAC ID: 5991003352 Enrollment ID: I20170823002533 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Esther P Soundar |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1861837320 PECOS PAC ID: 9638441850 Enrollment ID: I20170823003121 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tasneem Siddiqua |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1154634020 PECOS PAC ID: 8921314337 Enrollment ID: I20170829000726 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amir R Hajrasouliha |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1083916027 PECOS PAC ID: 9234458936 Enrollment ID: I20170829002394 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shaina L Schochat |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1649690579 PECOS PAC ID: 8729203195 Enrollment ID: I20170830000614 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Umer A Bhatti |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1255745568 PECOS PAC ID: 2567687759 Enrollment ID: I20170830002117 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Samuel Maghidman |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1821086703 PECOS PAC ID: 0547296907 Enrollment ID: I20170830002582 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Alex S Gilman |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1386608255 PECOS PAC ID: 0143201525 Enrollment ID: I20170920002097 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Yugandhar C Kalagara |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1285039602 PECOS PAC ID: 6608176128 Enrollment ID: I20170928002650 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bryan Rey Norkus |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1376957928 PECOS PAC ID: 9638394828 Enrollment ID: I20171003004967 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ranbir Singh |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1134531072 PECOS PAC ID: 0143596288 Enrollment ID: I20171018000563 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Theodore Ernest Wilson |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1699035030 PECOS PAC ID: 0941438568 Enrollment ID: I20171031002674 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stephen J Jordan |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1598055758 PECOS PAC ID: 9638316466 Enrollment ID: I20171108003018 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brittany Brinley |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1649616855 PECOS PAC ID: 7719278613 Enrollment ID: I20171110001500 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nyoka K Lamey |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1902325780 PECOS PAC ID: 3779849526 Enrollment ID: I20171117002084 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Natasha Raman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1861930042 PECOS PAC ID: 2365709037 Enrollment ID: I20171205002243 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Chunhai Hao |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1306804208 PECOS PAC ID: 4981666534 Enrollment ID: I20171208001002 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Suzanne Lappas |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1275049363 PECOS PAC ID: 0042579278 Enrollment ID: I20180117000063 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Paul M Wallach |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1487665675 PECOS PAC ID: 0244395697 Enrollment ID: I20180123002044 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Marappa Gownder Nalle |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1578877064 PECOS PAC ID: 1759523053 Enrollment ID: I20180201002566 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mounish Karlapudi |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1396165163 PECOS PAC ID: 4981820206 Enrollment ID: I20180202000341 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | James Keith Brown |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1245769355 PECOS PAC ID: 2466712831 Enrollment ID: I20180202000697 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sydney K Hall |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1942717533 PECOS PAC ID: 3274893466 Enrollment ID: I20180208000715 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Pamela M Dam |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1821599614 PECOS PAC ID: 7315200037 Enrollment ID: I20180411001258 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Samuel R Tredemeyer |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1366570855 PECOS PAC ID: 7315048451 Enrollment ID: I20180511000326 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Molly Anne Mcpheron |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1225476930 PECOS PAC ID: 4082855267 Enrollment ID: I20180601001182 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bridget C Thorne |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1366930331 PECOS PAC ID: 9537424023 Enrollment ID: I20180605000169 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Imran A Sethi |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1093914301 PECOS PAC ID: 0244313500 Enrollment ID: I20180615001865 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jay A Hildebrand |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1427269737 PECOS PAC ID: 2264615905 Enrollment ID: I20180625002110 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Monte Shaw Willis |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1548215528 PECOS PAC ID: 2567474778 Enrollment ID: I20180626000563 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Alyssa Dayne Swick |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1194110544 PECOS PAC ID: 1951613371 Enrollment ID: I20180628001206 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Krista Rath Allen |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1558758011 PECOS PAC ID: 2769793736 Enrollment ID: I20180628001273 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jakoda A Snider |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1063894517 PECOS PAC ID: 0345554390 Enrollment ID: I20180629002455 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sarah E Macgregor |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1477972024 PECOS PAC ID: 9537450523 Enrollment ID: I20180702002338 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ahsan Aslam |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1992180970 PECOS PAC ID: 6901152727 Enrollment ID: I20180710002170 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Aileen F Puno |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1114163664 PECOS PAC ID: 2365600475 Enrollment ID: I20180712003629 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | William Brian Kuhn |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1548451040 PECOS PAC ID: 6507848025 Enrollment ID: I20180719002271 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sarah N Book |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891281895 PECOS PAC ID: 0648527754 Enrollment ID: I20180720000831 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ross D Green |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1235526419 PECOS PAC ID: 7113231176 Enrollment ID: I20180723003326 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Katrina Alise Ducis |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1629367354 PECOS PAC ID: 0143541573 Enrollment ID: I20180724002860 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Abdirahim Mohamed Rashid |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1255713871 PECOS PAC ID: 3375857196 Enrollment ID: I20180725000130 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Elizabeth Ann Martin |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1609219021 PECOS PAC ID: 2961636113 Enrollment ID: I20180725000238 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gebran Khneizer |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1386039477 PECOS PAC ID: 4789986100 Enrollment ID: I20180726003332 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sachin B Shah |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1841684768 PECOS PAC ID: 2163724477 Enrollment ID: I20180807001641 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nakeeta L Stansberry |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649400896 PECOS PAC ID: 1658620026 Enrollment ID: I20180817001027 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kassem Bourgi |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1780948299 PECOS PAC ID: 8426280983 Enrollment ID: I20180821000750 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Allison M Tann |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164901724 PECOS PAC ID: 6507115300 Enrollment ID: I20180827002575 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Steven D Smith |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1386123446 PECOS PAC ID: 7517217268 Enrollment ID: I20180830002033 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Raechel E Serrano |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1376042655 PECOS PAC ID: 8022368588 Enrollment ID: I20180904000945 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michelle C Ziegler |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1811491491 PECOS PAC ID: 2264782788 Enrollment ID: I20180904003518 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kelly Diane Jenne |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1144767344 PECOS PAC ID: 6800147497 Enrollment ID: I20180920001536 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rohit Gulati |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1174965818 PECOS PAC ID: 4587896337 Enrollment ID: I20181008001291 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nadeem Najam |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1982669495 PECOS PAC ID: 9032178934 Enrollment ID: I20181012000679 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carmanny S Dinkins |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1083189146 PECOS PAC ID: 8527310754 Enrollment ID: I20181016002097 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Erin E Conboy |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1295099240 PECOS PAC ID: 5092952259 Enrollment ID: I20181019002447 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Uzochukwu Amadi |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1689961088 PECOS PAC ID: 7012226855 Enrollment ID: I20181026000399 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Emily M Gould |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1366824112 PECOS PAC ID: 3072827021 Enrollment ID: I20181106003270 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Dianna Marie Johnson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1851803456 PECOS PAC ID: 4183978323 Enrollment ID: I20181107000734 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Andrew J Wolfe |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1760869366 PECOS PAC ID: 8527372580 Enrollment ID: I20181110000327 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Anusha Vege |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1487040853 PECOS PAC ID: 9638423189 Enrollment ID: I20181119003064 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Joshua Tomas Richey |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1386739589 PECOS PAC ID: 3375887573 Enrollment ID: I20181128002716 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rachel Ann Cash |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1700352853 PECOS PAC ID: 3971847724 Enrollment ID: I20181204003966 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Margaret Marie Spolnik |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1134577851 PECOS PAC ID: 0547552127 Enrollment ID: I20181211002920 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shana C Zwick |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1518990738 PECOS PAC ID: 4082707781 Enrollment ID: I20181212003003 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lucas M Teel |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1104392257 PECOS PAC ID: 8628314069 Enrollment ID: I20190107001805 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lauren Knight |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1538632559 PECOS PAC ID: 8022354232 Enrollment ID: I20190109001112 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Fnu Jaydev |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1275915563 PECOS PAC ID: 9537471099 Enrollment ID: I20190122001549 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Saduf Ijaz Bilfaqi |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1215270087 PECOS PAC ID: 7012145261 Enrollment ID: I20190124000159 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Elie Jose Checo Heinsen |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1467764381 PECOS PAC ID: 9739322884 Enrollment ID: I20190305001800 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shakeel Choudhry |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1801258355 PECOS PAC ID: 3173863131 Enrollment ID: I20190329000661 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kathy L Newell |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1083726103 PECOS PAC ID: 0446384374 Enrollment ID: I20190417003064 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stephan George Dixon |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1396125589 PECOS PAC ID: 7416256607 Enrollment ID: I20190509000899 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Maria Stunkel |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1588042709 PECOS PAC ID: 9436464096 Enrollment ID: I20190513002799 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sheila Elaika Segura |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1891061370 PECOS PAC ID: 0446591101 Enrollment ID: I20190517001601 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Joseph Daniel Helfenberger |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1184074486 PECOS PAC ID: 4587956180 Enrollment ID: I20190522000041 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jacob C Halvorsen |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1326423930 PECOS PAC ID: 1153614888 Enrollment ID: I20190606001364 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | John-paul Lavik |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1518370923 PECOS PAC ID: 9931461126 Enrollment ID: I20190610001534 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michelle Ann Timmons |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1720173008 PECOS PAC ID: 9032442777 Enrollment ID: I20190611003071 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lauren C Mehner |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1285020685 PECOS PAC ID: 7214239771 Enrollment ID: I20190614000104 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Arefin Chowdhury |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1235589003 PECOS PAC ID: 5294028684 Enrollment ID: I20190620002014 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stephanie Lynn Reynolds |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1386095719 PECOS PAC ID: 6305139080 Enrollment ID: I20190624000263 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gal Marcan |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1932555844 PECOS PAC ID: 2567755184 Enrollment ID: I20190624001089 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Adam Maclauchlan |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1457702896 PECOS PAC ID: 6002109709 Enrollment ID: I20190624001181 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Khristian Sunga |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1417305434 PECOS PAC ID: 5799076543 Enrollment ID: I20190624001758 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bryce A Mohr |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1437536869 PECOS PAC ID: 7810201878 Enrollment ID: I20190624002815 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Catherine G Trigonis |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1760846877 PECOS PAC ID: 5395023238 Enrollment ID: I20190627000572 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jennifer Marie King |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1093163347 PECOS PAC ID: 3577854488 Enrollment ID: I20190702003060 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Alexander D'angelo |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1972998516 PECOS PAC ID: 8426363466 Enrollment ID: I20190709001658 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jacob John Wagner |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1700266079 PECOS PAC ID: 5597076406 Enrollment ID: I20190710002264 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ella Varney |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1205821691 PECOS PAC ID: 1951330935 Enrollment ID: I20190710002266 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | John Lewis Eisenlohr |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1386007011 PECOS PAC ID: 2567754153 Enrollment ID: I20190717002594 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | John Thompson Lind |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1407054042 PECOS PAC ID: 0244307817 Enrollment ID: I20190718003215 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Joanna J Campodonico |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1477973311 PECOS PAC ID: 8426328964 Enrollment ID: I20190723000673 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Richard J Fiorito |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1033673090 PECOS PAC ID: 0042546343 Enrollment ID: I20190724002634 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Meredith Leilani Koontz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1861053068 PECOS PAC ID: 5799011813 Enrollment ID: I20190727000353 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Isra Ibrahim |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1659722460 PECOS PAC ID: 9234465352 Enrollment ID: I20190727000378 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mark Kandary |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1104277235 PECOS PAC ID: 2365729019 Enrollment ID: I20190729001584 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shai Mandelboim |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1609209600 PECOS PAC ID: 7315231107 Enrollment ID: I20190803000052 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mary E Connell |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1396194403 PECOS PAC ID: 7517259112 Enrollment ID: I20190809000610 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carina Thea Marcella David |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1629424254 PECOS PAC ID: 9133411846 Enrollment ID: I20190821001203 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Christine Megan Nix |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1013362839 PECOS PAC ID: 2365731874 Enrollment ID: I20190822000093 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Clair Ann Francomano |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1083657613 PECOS PAC ID: 8325072390 Enrollment ID: I20190822000714 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sukhwinder Singh |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1164871174 PECOS PAC ID: 2769754332 Enrollment ID: I20190823002382 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gabrielle Christine Geddes |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1972803161 PECOS PAC ID: 8325281363 Enrollment ID: I20190823003249 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Faiza Amin |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1548618291 PECOS PAC ID: 9830476555 Enrollment ID: I20190827001396 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Banu Berkem |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1225681992 PECOS PAC ID: 9638408834 Enrollment ID: I20190913001184 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shelly D Timmons |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1619950854 PECOS PAC ID: 8921293986 Enrollment ID: I20190923002228 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bradley N Bohnstedt |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1952568271 PECOS PAC ID: 4587800081 Enrollment ID: I20190925001899 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Matthew M Amayun |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568011005 PECOS PAC ID: 2466782008 Enrollment ID: I20190925001937 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Melissa G Collier |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1003025511 PECOS PAC ID: 9436435633 Enrollment ID: I20190926000665 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Melissa W Ko |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1548325707 PECOS PAC ID: 9739253931 Enrollment ID: I20191003000778 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Courtney Sue Bono |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1629626213 PECOS PAC ID: 3779814595 Enrollment ID: I20191009001774 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Khaleel Al-obaidy |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1649665324 PECOS PAC ID: 6901177393 Enrollment ID: I20191031001566 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Allie Suzanne Caveney |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356997779 PECOS PAC ID: 6204168685 Enrollment ID: I20191105000549 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Divya R Nallapuram |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1730533373 PECOS PAC ID: 7113219122 Enrollment ID: I20191107000820 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Elizabeth Ann Adams |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164847372 PECOS PAC ID: 8729393160 Enrollment ID: I20191115001363 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lindsay Nicole Rich |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1326683210 PECOS PAC ID: 4082047279 Enrollment ID: I20191202000728 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Elizabeth Anne Snodgrass-stringer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1588207310 PECOS PAC ID: 5395178149 Enrollment ID: I20191209001665 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Toni Suarez |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1073156360 PECOS PAC ID: 5496188070 Enrollment ID: I20191212001817 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Danielle N Mcclendon |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1609426410 PECOS PAC ID: 7416381629 Enrollment ID: I20191221000403 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michele R Spargur |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518424464 PECOS PAC ID: 5597199729 Enrollment ID: I20191223000139 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Hector Alonso Mesa Corrales |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1811082209 PECOS PAC ID: 5395831507 Enrollment ID: I20200109000164 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nikolay Kirilov Popnikolov |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1821041187 PECOS PAC ID: 9830292929 Enrollment ID: I20200114001659 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Muhammad Ajmal A Panezai |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1982954442 PECOS PAC ID: 6204057219 Enrollment ID: I20200211000395 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kenneth Jia En Lim |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1316280381 PECOS PAC ID: 1052555182 Enrollment ID: I20200214002305 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Todd L Randolph |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1740249192 PECOS PAC ID: 4789661547 Enrollment ID: I20200218000109 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Fatmah H Albaaj |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1023373081 PECOS PAC ID: 8325274889 Enrollment ID: I20200407001926 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Elizabeth Mae Cowgill |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1558899740 PECOS PAC ID: 7911276035 Enrollment ID: I20200505002958 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Audrey Chun |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1144615048 PECOS PAC ID: 8628370228 Enrollment ID: I20200507001443 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nnabugo D Ozurumba |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1154732667 PECOS PAC ID: 3577805217 Enrollment ID: I20200508000100 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel T Cheriye |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1225558208 PECOS PAC ID: 3274802459 Enrollment ID: I20200513001213 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kathryn E Davis |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1144681917 PECOS PAC ID: 8325345903 Enrollment ID: I20200515000570 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jacob Lew Ramsey-morrow |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1457708364 PECOS PAC ID: 5294028700 Enrollment ID: I20200518001850 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tieying Hou |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1558780833 PECOS PAC ID: 4981025251 Enrollment ID: I20200522002299 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brock D Vanderbush |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1396162749 PECOS PAC ID: 4385937762 Enrollment ID: I20200608001415 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Manognya Muttineni |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1023490208 PECOS PAC ID: 6901119908 Enrollment ID: I20200608002932 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Esmeralda Gutierrez-asis |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1881959526 PECOS PAC ID: 2860637006 Enrollment ID: I20200618003078 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Megan N Nyee Macki |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1417578584 PECOS PAC ID: 0547682411 Enrollment ID: I20200623000436 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Harinder P Kaur |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1851822266 PECOS PAC ID: 3072886571 Enrollment ID: I20200623002315 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Virendra Rajendrakumar Desai |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1497016182 PECOS PAC ID: 5597187005 Enrollment ID: I20200629002739 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kevin Denis Schwartz |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1700314077 PECOS PAC ID: 4789956988 Enrollment ID: I20200706002470 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Richard Michael Schroeder |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1578957650 PECOS PAC ID: 3072847524 Enrollment ID: I20200708003503 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brandon Cole Lane |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1851730782 PECOS PAC ID: 9830498260 Enrollment ID: I20200714002096 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Priyanka Hiten Parekh |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1780034223 PECOS PAC ID: 6608167598 Enrollment ID: I20200716000290 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ruth E Stanton |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1154785954 PECOS PAC ID: 9436421260 Enrollment ID: I20200716003413 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tariku T Gudura |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1255861001 PECOS PAC ID: 2668773268 Enrollment ID: I20200717003053 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Christopher Ryan Moriarty |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1194139816 PECOS PAC ID: 1850653247 Enrollment ID: I20200720003234 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Laura Warmke |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1467879502 PECOS PAC ID: 6800019373 Enrollment ID: I20200721003336 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Yan Yang |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1467974055 PECOS PAC ID: 0547684565 Enrollment ID: I20200723002458 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ekanga Sunday Petters |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1144751827 PECOS PAC ID: 8527331321 Enrollment ID: I20200727000534 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rachel Paula Kowal |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1982761979 PECOS PAC ID: 8123151313 Enrollment ID: I20200727001982 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Caitrin M Kelly |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1255712667 PECOS PAC ID: 9638487242 Enrollment ID: I20200727002151 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Samuel Eugene Franks |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1982011904 PECOS PAC ID: 5496975591 Enrollment ID: I20200727003386 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kunal Gupta |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1316203805 PECOS PAC ID: 9032364864 Enrollment ID: I20200729001769 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Yaling Liu |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1417305509 PECOS PAC ID: 7012203839 Enrollment ID: I20200731001175 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stacie Hirota |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1720442353 PECOS PAC ID: 1052608544 Enrollment ID: I20200803000182 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Omer Abdelaziz Mohammed Saeed |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1659754711 PECOS PAC ID: 8325347784 Enrollment ID: I20200804003316 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Karen Scharenberg Amstutz |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1407983976 PECOS PAC ID: 8325463458 Enrollment ID: I20200805003137 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Pavan Patel |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1508390592 PECOS PAC ID: 2365711520 Enrollment ID: I20200806002293 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Abhilasha Jarori |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1619298080 PECOS PAC ID: 1254565344 Enrollment ID: I20200811002145 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Akshita Patel |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1639603947 PECOS PAC ID: 7719256981 Enrollment ID: I20200812002339 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Chandra Mohan Thippanna |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1730517061 PECOS PAC ID: 2466688155 Enrollment ID: I20200812002710 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ann Hulme |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1124402920 PECOS PAC ID: 6103133632 Enrollment ID: I20200819002932 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sarah Spitnagle Bosslet |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1962462531 PECOS PAC ID: 3870505928 Enrollment ID: I20200821000383 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael J Hwang |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1871904532 PECOS PAC ID: 3375973811 Enrollment ID: I20200821002193 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kelsey M Knight |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1043822844 PECOS PAC ID: 7214354026 Enrollment ID: I20200825002231 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mithila Gongireddy |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1366971814 PECOS PAC ID: 9436576915 Enrollment ID: I20200828001376 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mina S Youssef |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1447783683 PECOS PAC ID: 3173893971 Enrollment ID: I20200831000709 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amy Patel Gabbard |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1093122632 PECOS PAC ID: 8921330705 Enrollment ID: I20200911000316 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Manasa Surasani Reddy |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1982024634 PECOS PAC ID: 8426308263 Enrollment ID: I20201009001999 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carmen R Frede |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1487267332 PECOS PAC ID: 5496175408 Enrollment ID: I20201013002276 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Anna M Schultheis |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871137786 PECOS PAC ID: 1254751019 Enrollment ID: I20201015002260 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Peter Hanna Halim Mousa |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1548780125 PECOS PAC ID: 0042630808 Enrollment ID: I20201015002408 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kara Irene Anoskey |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1235732256 PECOS PAC ID: 5597176057 Enrollment ID: I20201204001710 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mark Vaughn Larkins |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1740230317 PECOS PAC ID: 3072565175 Enrollment ID: I20210114000745 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rachael Anne Aust |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1154925634 PECOS PAC ID: 5395158281 Enrollment ID: I20210114001029 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brittany Taylor Kocoj |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1962002238 PECOS PAC ID: 6901219898 Enrollment ID: I20210114001145 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lynda Jean Norris |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871124545 PECOS PAC ID: 0042624850 Enrollment ID: I20210205000639 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jessica C Ahonen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1659956951 PECOS PAC ID: 9537576848 Enrollment ID: I20210405001330 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brandon Allen Umphress |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1982090361 PECOS PAC ID: 7719269521 Enrollment ID: I20210615001611 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Zheyu Lu |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1023514478 PECOS PAC ID: 7214273242 Enrollment ID: I20210623001195 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel Bruce Eddelman |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1861807844 PECOS PAC ID: 7517265259 Enrollment ID: I20210624001484 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jason Kippenbrock |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1093208100 PECOS PAC ID: 3678828266 Enrollment ID: I20210713001391 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael Joseph Mcmanus |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1922680487 PECOS PAC ID: 2062814023 Enrollment ID: I20210713002747 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Victoria S Sharaf |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1952808156 PECOS PAC ID: 4183979990 Enrollment ID: I20210722001621 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | James Pastrnak |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1639528235 PECOS PAC ID: 0941588891 Enrollment ID: I20210728002180 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bradley L Collins |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1639666423 PECOS PAC ID: 9032513874 Enrollment ID: I20210802001522 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Muhammad Rishi |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1487898011 PECOS PAC ID: 0840316782 Enrollment ID: I20210803001262 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Wade Garret Kvatum |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1447743398 PECOS PAC ID: 9537414149 Enrollment ID: I20210804001478 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gordon G Mao |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1063854651 PECOS PAC ID: 7517255136 Enrollment ID: I20210804001545 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Clem J Wegman |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1366936601 PECOS PAC ID: 3870849631 Enrollment ID: I20210804004132 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Katrina Michelle Collins |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1770995144 PECOS PAC ID: 1153750237 Enrollment ID: I20210810000295 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lindsey Anne Harden Atwood |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1356879068 PECOS PAC ID: 3072881986 Enrollment ID: I20210811001359 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Natascia V Borsellino |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1528552965 PECOS PAC ID: 9739435058 Enrollment ID: I20210817000391 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Swathi B Jallipalli |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1306341730 PECOS PAC ID: 1052660511 Enrollment ID: I20210817002189 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tyler Joseph Knight |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1184157133 PECOS PAC ID: 0446655203 Enrollment ID: I20210818000413 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Angela M Richardson |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1316289218 PECOS PAC ID: 1759703994 Enrollment ID: I20210824000351 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Victoria J Miller |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1679936009 PECOS PAC ID: 6406149384 Enrollment ID: I20210824000365 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kevin R Gordon |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124791678 PECOS PAC ID: 8123423522 Enrollment ID: I20210824000508 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Swetha Jalli |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1114372489 PECOS PAC ID: 4981977865 Enrollment ID: I20210824001036 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Muhammad Y Jan |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1679988281 PECOS PAC ID: 9335364835 Enrollment ID: I20210824001395 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Holly Nicole Harding |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1376037887 PECOS PAC ID: 4789930157 Enrollment ID: I20210824001431 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Savannah Jayne Morris |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1780232520 PECOS PAC ID: 6103221536 Enrollment ID: I20210824002042 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jignesh Kishor Tailor |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1629669643 PECOS PAC ID: 2668887308 Enrollment ID: I20210824002530 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Laura Prince |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1194187146 PECOS PAC ID: 1456644673 Enrollment ID: I20210824002810 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rajesh Kumar |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1174828271 PECOS PAC ID: 2264670629 Enrollment ID: I20210825001731 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shannon S Dillon |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1770796955 PECOS PAC ID: 6406946326 Enrollment ID: I20210825002288 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Roopsi Bring |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1750873030 PECOS PAC ID: 2466708789 Enrollment ID: I20210831002646 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Priya Joshi |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1013302769 PECOS PAC ID: 3375839962 Enrollment ID: I20210831002717 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nicholas W Berry |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1386147866 PECOS PAC ID: 3971850884 Enrollment ID: I20210909000758 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Eric T Degraaf |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1316614605 PECOS PAC ID: 1153727342 Enrollment ID: I20210914001799 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ahmed M Jlasi |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1801386412 PECOS PAC ID: 0840697447 Enrollment ID: I20210924000228 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Laila Mossa-basha |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1669978375 PECOS PAC ID: 4688921943 Enrollment ID: I20210927000802 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Swetha Parvataneni |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1174931406 PECOS PAC ID: 0042582116 Enrollment ID: I20210930000599 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Soha Khan Rizvi |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1285085654 PECOS PAC ID: 6800155516 Enrollment ID: I20211015001429 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jill S Dana |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1063184869 PECOS PAC ID: 0547658874 Enrollment ID: I20211019002036 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amanda M Saratsis |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1164673141 PECOS PAC ID: 7911224308 Enrollment ID: I20211115000284 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kerry B Nagee |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1467749598 PECOS PAC ID: 0244450757 Enrollment ID: I20211123001177 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Elvira Shreder Payne |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1306338454 PECOS PAC ID: 1254681604 Enrollment ID: I20211202001074 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Charles Austin Curtis |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1013413806 PECOS PAC ID: 6305247172 Enrollment ID: I20211208000433 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Benjamin Jay Byriel |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1609367101 PECOS PAC ID: 9638424443 Enrollment ID: I20211221001989 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brooke Michelle Hansen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164189361 PECOS PAC ID: 9436541547 Enrollment ID: I20220124001355 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lori A Stanley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1346906526 PECOS PAC ID: 9739572215 Enrollment ID: I20220204000592 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Pierre U Etienne |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1124468400 PECOS PAC ID: 2961714084 Enrollment ID: I20220218001349 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | William R Bell |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1720269251 PECOS PAC ID: 4486927019 Enrollment ID: I20220302000595 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sabrina Fabara |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1558717520 PECOS PAC ID: 4183055197 Enrollment ID: I20220302001682 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brynlee Johnson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1407500382 PECOS PAC ID: 2961897962 Enrollment ID: I20220309001417 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Gizem Tumer |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1396906566 PECOS PAC ID: 1759504491 Enrollment ID: I20220322000632 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sun Mi Lee |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1205069440 PECOS PAC ID: 6507252624 Enrollment ID: I20220329002382 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nabeel Awan |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1134876097 PECOS PAC ID: 7416343264 Enrollment ID: I20220405000973 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Angela Marie Scaringe |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174284921 PECOS PAC ID: 8527454206 Enrollment ID: I20220405002699 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Loren R Schubert |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1437611332 PECOS PAC ID: 0143558593 Enrollment ID: I20220419000961 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Dongwei Zhang |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1437415239 PECOS PAC ID: 9335434182 Enrollment ID: I20220426001148 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lu Jun Pan |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1477843449 PECOS PAC ID: 3779862396 Enrollment ID: I20220427000728 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Adrian Lugo |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1215496237 PECOS PAC ID: 0345578175 Enrollment ID: I20220513000954 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Natika L Washington |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1346883030 PECOS PAC ID: 8123405073 Enrollment ID: I20220513001640 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brandon John Heeger |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1356734503 PECOS PAC ID: 4981952439 Enrollment ID: I20220516001053 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ryan Ray House |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1407389679 PECOS PAC ID: 4385021146 Enrollment ID: I20220517000512 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Hayder Abbood |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1922448141 PECOS PAC ID: 2668768649 Enrollment ID: I20220523000626 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Anna L Skupin |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1831739416 PECOS PAC ID: 9234516667 Enrollment ID: I20220524001701 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Martina Marie Natali |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013662071 PECOS PAC ID: 7214315597 Enrollment ID: I20220526002186 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Andrea Michelle Sellmeyer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1588304133 PECOS PAC ID: 8921486085 Enrollment ID: I20220601001240 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Arminder Singh Johal |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1942794227 PECOS PAC ID: 1951658111 Enrollment ID: I20220603000661 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Murtaza Ali |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1801457650 PECOS PAC ID: 5294062162 Enrollment ID: I20220604000350 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Haneen Ayed Shawkat Mohammad |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1104251040 PECOS PAC ID: 8325278278 Enrollment ID: I20220606000321 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Katherine Michelle Brown |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1396234308 PECOS PAC ID: 2961739347 Enrollment ID: I20220607002671 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Evan-jacob Bearinger Garcia |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1073046801 PECOS PAC ID: 2365864097 Enrollment ID: I20220608001551 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Xin Zhang |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1851827372 PECOS PAC ID: 1052667375 Enrollment ID: I20220610000311 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nichole L Lepage |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1225558125 PECOS PAC ID: 0547530065 Enrollment ID: I20220615002086 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Irum Mahmood |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1699334367 PECOS PAC ID: 5496089534 Enrollment ID: I20220616002683 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Abigail Pence |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1386384493 PECOS PAC ID: 6204215478 Enrollment ID: I20220617001136 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Arslan Zafar Chaudhry |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1467017624 PECOS PAC ID: 5395124598 Enrollment ID: I20220617001752 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Paul Thomas Mingo |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1891355871 PECOS PAC ID: 9739414962 Enrollment ID: I20220621001072 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Neggin Afsari |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1861953416 PECOS PAC ID: 8729313408 Enrollment ID: I20220621001328 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ayesha Badar |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1619462330 PECOS PAC ID: 5193076800 Enrollment ID: I20220621003200 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shannon Nicole Hauger |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1427798867 PECOS PAC ID: 8527447556 Enrollment ID: I20220622002625 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brent Matthew Molden |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1073975629 PECOS PAC ID: 8921487760 Enrollment ID: I20220624000514 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Irene A Carrothers |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1003041831 PECOS PAC ID: 0547418238 Enrollment ID: I20220624000942 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jenna D Loveday |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1083101653 PECOS PAC ID: 1850640103 Enrollment ID: I20220627002912 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Daniel Joseph Schramm |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1700383064 PECOS PAC ID: 4284981531 Enrollment ID: I20220628002137 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kunal Suri |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1033630256 PECOS PAC ID: 4587044110 Enrollment ID: I20220629001425 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ann E Schmitt |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1801359666 PECOS PAC ID: 6406180249 Enrollment ID: I20220705001930 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kapesh Kunwar |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1497319040 PECOS PAC ID: 5991033201 Enrollment ID: I20220707002750 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David Beckham Mullen |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1356803365 PECOS PAC ID: 6800121906 Enrollment ID: I20220709000234 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Thomas Robert Freije |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1003379090 PECOS PAC ID: 3072847037 Enrollment ID: I20220711003559 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Katie Sue Carson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1346703840 PECOS PAC ID: 7517291503 Enrollment ID: I20220714002780 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amber Marie Sweet |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1093455404 PECOS PAC ID: 5890176317 Enrollment ID: I20220714003773 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ivan Antonio Gonzalez Arostegui |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1679925697 PECOS PAC ID: 3779964234 Enrollment ID: I20220715000908 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Allysa Hannah Nagy |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1932697976 PECOS PAC ID: 9537414370 Enrollment ID: I20220719002994 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Steven Michael Wakeman |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1841639101 PECOS PAC ID: 4880983493 Enrollment ID: I20220725000496 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jill Caroline Penman |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1497243802 PECOS PAC ID: 4183989858 Enrollment ID: I20220727001840 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mohamed Amin Mustafa |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1245680354 PECOS PAC ID: 5496048670 Enrollment ID: I20220728001173 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Saul Wilson |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1871700690 PECOS PAC ID: 2163574666 Enrollment ID: I20220802002200 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nathan Buckley |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1417510033 PECOS PAC ID: 8123350451 Enrollment ID: I20220810000358 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Aysam H Mahmoud |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1598228629 PECOS PAC ID: 4183007966 Enrollment ID: I20220811000289 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rabia Qaiser |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1639365802 PECOS PAC ID: 7911149224 Enrollment ID: I20220811000989 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Anna Geraldina Pendrey Guillen |
---|---|
Provider Type | Practitioner - Geriatric Medicine |
Provider Identifiers | NPI Number: 1437644911 PECOS PAC ID: 2062768989 Enrollment ID: I20220816003168 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rafael J Rolon Rivera |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1316233661 PECOS PAC ID: 1456570738 Enrollment ID: I20220825000730 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Savanna H Bruski |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1922561711 PECOS PAC ID: 2062746563 Enrollment ID: I20220901000328 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kavita Umrau |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1275086530 PECOS PAC ID: 1355686189 Enrollment ID: I20220902000610 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Christopher Brian Thomas |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1588077234 PECOS PAC ID: 1557387255 Enrollment ID: I20220912001920 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amanda Daufae Dobbins |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1407317787 PECOS PAC ID: 1254716970 Enrollment ID: I20220916001203 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Adele O Kraft |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1528350915 PECOS PAC ID: 2961651591 Enrollment ID: I20220917000272 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Katie L Buel |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1598177008 PECOS PAC ID: 7618279514 Enrollment ID: I20221007001042 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Omar Salman |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1013408939 PECOS PAC ID: 1557626074 Enrollment ID: I20221008000282 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Abigail K Wegehaupt |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1861952814 PECOS PAC ID: 9234464751 Enrollment ID: I20221013001723 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Heather R Uberto |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1093434433 PECOS PAC ID: 9436525425 Enrollment ID: I20221017000681 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jessica L Davis |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1750607966 PECOS PAC ID: 2365673969 Enrollment ID: I20221019001935 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | John S Underwood |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1508391194 PECOS PAC ID: 6709153315 Enrollment ID: I20221021001475 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michelle L Ritchey |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1578286928 PECOS PAC ID: 1557738960 Enrollment ID: I20221027001370 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sabina L Silver |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1558624684 PECOS PAC ID: 4082846217 Enrollment ID: I20221104001958 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Hannah E Delucio |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1417664327 PECOS PAC ID: 1052789567 Enrollment ID: I20221114003148 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Simona L Wildman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1700509338 PECOS PAC ID: 8022486315 Enrollment ID: I20221117000699 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jordan Rebekah Maxwell |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528781804 PECOS PAC ID: 1254709454 Enrollment ID: I20221118002192 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ahsan Siddiqi |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1174919021 PECOS PAC ID: 9032410949 Enrollment ID: I20221209002204 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Navin Chandra Ravishankar |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1194285221 PECOS PAC ID: 3173859964 Enrollment ID: I20221209002403 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Stacia L Frazee |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124770466 PECOS PAC ID: 2163891367 Enrollment ID: I20221209002625 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Peter Joseph Gindling |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1023726106 PECOS PAC ID: 8527437433 Enrollment ID: I20221216000261 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jessica Anne Schuster |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1487018149 PECOS PAC ID: 7416292750 Enrollment ID: I20221230002228 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Andres Martin Acosta |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1275948127 PECOS PAC ID: 1759690910 Enrollment ID: I20230105002823 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Brooke Ratcliffe |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1710649496 PECOS PAC ID: 0042681330 Enrollment ID: I20230124003461 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michael Feldman |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1447294335 PECOS PAC ID: 7517909302 Enrollment ID: I20230130000653 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Syed Hammad H Jafri |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1922256858 PECOS PAC ID: 1557534351 Enrollment ID: I20230202002938 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Khushboo Doshi |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1407274152 PECOS PAC ID: 9830472505 Enrollment ID: I20230207000784 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Murad Akjah |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1386366060 PECOS PAC ID: 2961874607 Enrollment ID: I20230207001010 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jennifer K Amador |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1114631884 PECOS PAC ID: 8628441664 Enrollment ID: I20230222002056 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Megan K Tenbarge |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1548966963 PECOS PAC ID: 2961875703 Enrollment ID: I20230227001464 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Nicole D Poteet |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1831896471 PECOS PAC ID: 4082087259 Enrollment ID: I20230309000576 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kemin Xu |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1710414339 PECOS PAC ID: 7214393479 Enrollment ID: I20230515002073 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carina A Dehner |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1033695648 PECOS PAC ID: 9537499868 Enrollment ID: I20230522000436 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rose Chisenga |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1043871486 PECOS PAC ID: 6608104443 Enrollment ID: I20230523000806 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kenneth N Ofori |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1508392754 PECOS PAC ID: 1951649235 Enrollment ID: I20230523002071 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kyle G Cotten |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1437610003 PECOS PAC ID: 2264767573 Enrollment ID: I20230531000770 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Muhammad Ahmad |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1023562642 PECOS PAC ID: 7517252901 Enrollment ID: I20230531000901 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Andrew D Young |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1528590379 PECOS PAC ID: 8426326646 Enrollment ID: I20230605000347 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kirandeep Banga |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1033734645 PECOS PAC ID: 4486055373 Enrollment ID: I20230608002671 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shivam Hasmukh Patel |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1679035018 PECOS PAC ID: 6406189356 Enrollment ID: I20230614002674 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Angela Kuo |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1235525445 PECOS PAC ID: 4486975042 Enrollment ID: I20230615000561 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Diego F Armas Cadavid |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1962192021 PECOS PAC ID: 8325406846 Enrollment ID: I20230615001124 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Zachary R Johnson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1043875883 PECOS PAC ID: 9537582937 Enrollment ID: I20230615002087 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Molly Elizaebth Lee |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1992324313 PECOS PAC ID: 3476975731 Enrollment ID: I20230615002278 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Agnes E Davenport |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1740970854 PECOS PAC ID: 8729446281 Enrollment ID: I20230615002609 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Kenneth A Moore |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1013304054 PECOS PAC ID: 8426437948 Enrollment ID: I20230622001863 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sharmilla Segar |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1396309969 PECOS PAC ID: 1153655816 Enrollment ID: I20230624000172 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Sebastian Ruiz |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1851910509 PECOS PAC ID: 0345661146 Enrollment ID: I20230627000258 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Rada Cretu |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1760172118 PECOS PAC ID: 4486012267 Enrollment ID: I20230627001210 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Benjamin Scott Bacon |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1386263168 PECOS PAC ID: 8022430016 Enrollment ID: I20230627001213 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jordan Marie Rogers Lucas |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1487274577 PECOS PAC ID: 6406277292 Enrollment ID: I20230627002145 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Andrew Gust Koustenis |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1821559709 PECOS PAC ID: 0749683175 Enrollment ID: I20230710003077 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carleigh N Bruce |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1043772858 PECOS PAC ID: 8729403746 Enrollment ID: I20230712000158 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jessica L Hata |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1770809410 PECOS PAC ID: 2062726326 Enrollment ID: I20230712000488 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Joseph D Bogaard |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1962943167 PECOS PAC ID: 0446520472 Enrollment ID: I20230714000369 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David A Camp |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1508328956 PECOS PAC ID: 1254666936 Enrollment ID: I20230714003117 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Maham Fatima |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1063028009 PECOS PAC ID: 4880013705 Enrollment ID: I20230715000696 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Seth Alexander Hunter |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1326667106 PECOS PAC ID: 7810319183 Enrollment ID: I20230719003727 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Carli P Whittington |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1174052856 PECOS PAC ID: 8224391305 Enrollment ID: I20230720003353 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Massood Mohammadi |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1932899051 PECOS PAC ID: 0244691814 Enrollment ID: I20230728001646 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Scott A Childers |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1265750236 PECOS PAC ID: 9234371725 Enrollment ID: I20230731001869 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Varsha Nair |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1659802734 PECOS PAC ID: 6002152840 Enrollment ID: I20230803001143 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Jacob Sama |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1639593775 PECOS PAC ID: 3779882758 Enrollment ID: I20230803004425 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Mert Sevgi |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1427662519 PECOS PAC ID: 4082033253 Enrollment ID: I20230804000551 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Courtney M Jackson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1013533926 PECOS PAC ID: 7719300292 Enrollment ID: I20230804000959 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Leah Kathryn Westrick |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1659990406 PECOS PAC ID: 9537581624 Enrollment ID: I20230810001848 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Naser A Kafeel |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1003437054 PECOS PAC ID: 8527450840 Enrollment ID: I20230822001589 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Michelle N Mcclory |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1821479601 PECOS PAC ID: 7618330531 Enrollment ID: I20230825000168 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Ashley M Kirchhoff |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1548942931 PECOS PAC ID: 7517321649 Enrollment ID: I20230907004314 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Katherine A Mansalis |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1255589941 PECOS PAC ID: 4486897766 Enrollment ID: I20230919000768 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | David B Mcfarland |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1740066943 PECOS PAC ID: 8224482575 Enrollment ID: I20230920003778 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tarachandra M Narumanchi |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1538253570 PECOS PAC ID: 3779512215 Enrollment ID: I20230926003079 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Matthew W Pease |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1114308558 PECOS PAC ID: 0749634483 Enrollment ID: I20230928001584 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Haseeba Khan |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1184148223 PECOS PAC ID: 8628340007 Enrollment ID: I20231010000328 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Tiffani B Wenck |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1376323469 PECOS PAC ID: 3678929759 Enrollment ID: I20231025003071 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Hannah J Harmsen |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1366897894 PECOS PAC ID: 3577973932 Enrollment ID: I20231031002132 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Amos Mwago Kangau |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679353189 PECOS PAC ID: 7315393808 Enrollment ID: I20231108000171 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shelby P Arles |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1306568944 PECOS PAC ID: 8628426293 Enrollment ID: I20231121002575 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Lisa M Rickard |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1457068439 PECOS PAC ID: 9537538368 Enrollment ID: I20231213002877 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Britani N Frame |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1043086283 PECOS PAC ID: 8022468768 Enrollment ID: I20231221001562 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Robyn K Zaenglein |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1497437644 PECOS PAC ID: 2769832252 Enrollment ID: I20231226000625 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Prentice R Ruth |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1982470902 PECOS PAC ID: 0143672568 Enrollment ID: I20240122000357 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Shannon Michelle Gullion |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891565842 PECOS PAC ID: 9830532126 Enrollment ID: I20240202002583 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Provider Name | Bret C Mobley |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1184812133 PECOS PAC ID: 0345393948 Enrollment ID: I20240220000257 |
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
News Archive
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.
...suggests research published ahead of print in Heart. Most of those who received the treatment were still alive five years later and had half the risk of death of their peers in the general population, the research reveals.
A technology designed to treat injured warfighters on the battlefield is proving its worth to civilian emergency-response teams.
› Verified 1 days ago
Moazzam Habib Md Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 9240 N Meridian St, Suite 240, Indianapolis, IN 46260 Phone: 317-571-0030 Fax: 317-571-0031 | |
Shalom 56th Street-new Access Point Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5750 W 56th St, Indianapolis, IN 46254 Phone: 317-291-7422 Fax: 317-291-4912 | |
Franciscan Health Indianapolis & Mooresville Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5230a East Stop 11 Road, Suite 250, Indianapolis, IN 46237 Phone: 317-528-8921 Fax: 317-528-6916 | |
Evernorth Care Providers - Delaware Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 8888 Keystone Xing Ste 1300, Indianapolis, IN 46240 Phone: 773-292-4800 Fax: 312-564-4059 | |
Eskenazi Health Center Cottage Corner Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1434 Shelby St, Indianapolis, IN 46203 Phone: 317-655-3200 Fax: 317-655-3210 | |
Hello Wellness Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1040 E 86th St, Suite 48-a, Indianapolis, IN 46240 Phone: 317-569-1800 | |
Indiana Neurodiagnostics, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9465 Counselors Row, Ste. 200 Office 257, Indianapolis, IN 46240 Phone: 317-614-0310 Fax: 866-279-4704 |